Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.pharmthera.2020.107628 http://scihub22266oqcxt.onion/10.1016/j.pharmthera.2020.107628 32653530!7346797!32653530     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Pharmacol+Ther 2020 ; 215 (ä): 107628 Nephropedia Template TP {{tp|p=32653530|t=2020. Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities |pdf=|usr=}}{{32653530}} gab.com Text Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities JO: Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=32653530 #FOAvip The coronavirus disease 2019 (COVID-19) pandemic is caused by a newly emerged coronavirus (CoV) called Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). COVID-19 patients with cardiovascular disease (CVD) comorbidities have significantly increased morbidity and mortality. The use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor type 1 blockers (ARBs) improve CVD outcomes; however, there is concern that they may worsen the prognosis of CVD patients that become infected with SARS-CoV-2 because the virus uses the ACE2 receptor to bind to and subsequently infect host cells. Thus, some health care providers and media sources have questioned the continued use of ACE inhibitors and ARBs. In this brief review, we discuss the effect of ACE inhibitor-induced bradykinin on the cardiovascular system, on the renin-angiotensin-aldosterone system (RAAS) regulation in COVID-19 patients, and analyze recent clinical studies regarding patients treated with RAAS inhibitors. We propose that the application of RAAS inhibitors for COVID-19 patients with CVDs may be beneficial rather than harmful. Twit Text FOAVip Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities ????Pharmacol Ther http://www.kidney.de/pget.php?&tw=1&pmid=32653530 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32653530 #FOAvip English Wikipedia <ref>{{Cite pmid|32653530}}</ref> Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities #MMPMID32653530 Wang JJ; Edin ML; Zeldin DC; Li C; Wang DW; Chen C Pharmacol Ther 2020[Nov]; 215 (ä): 107628 PMID32653530show ga The coronavirus disease 2019 (COVID-19) pandemic is caused by a newly emerged coronavirus (CoV) called Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). COVID-19 patients with cardiovascular disease (CVD) comorbidities have significantly increased morbidity and mortality. The use of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor type 1 blockers (ARBs) improve CVD outcomes; however, there is concern that they may worsen the prognosis of CVD patients that become infected with SARS-CoV-2 because the virus uses the ACE2 receptor to bind to and subsequently infect host cells. Thus, some health care providers and media sources have questioned the continued use of ACE inhibitors and ARBs. In this brief review, we discuss the effect of ACE inhibitor-induced bradykinin on the cardiovascular system, on the renin-angiotensin-aldosterone system (RAAS) regulation in COVID-19 patients, and analyze recent clinical studies regarding patients treated with RAAS inhibitors. We propose that the application of RAAS inhibitors for COVID-19 patients with CVDs may be beneficial rather than harmful. |*Betacoronavirus/drug effects/physiology[MESH] |*Cardiovascular Diseases/drug therapy/epidemiology/metabolism[MESH] |*Coronavirus Infections/epidemiology/therapy/virology[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/epidemiology/therapy/virology[MESH] |Angiotensin Receptor Antagonists/*pharmacology[MESH] |Angiotensin-Converting Enzyme Inhibitors/*pharmacology[MESH] |COVID-19[MESH] |Comorbidity[MESH] |Humans[MESH]Good or bad: Application of RAAS inhibitors in COVID-19 patients with (epmc).pdf DeepDyve Pubget Overpricing